IL6 and Sepsis: Interestingly, in a study of 2634 sepsis patients, treatment with the anti-TNF antibody (Ab) afelimomab resulted in a modest but significant reduction in 28-day mortality if serum IL-6 levels were > 1000 pg/mL, while patients with lower IL-6 levels did not benefit from treatment [14].